Format

Send to

Choose Destination
Vaccines (Basel). 2016 Aug 6;4(3). pii: E28. doi: 10.3390/vaccines4030028.

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.

Author information

1
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. belal.chaudhary@cantab.net.
2
Cancer Center, Qatar Biomedical Research Institute and College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha 5825, Qatar. eelkord@qf.org.qa.
3
College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE. eelkord@qf.org.qa.
4
Institute of Cancer Sciences, University of Manchester, Manchester M20 4BX, UK. eelkord@qf.org.qa.
5
Biomedical Research Centre, School of Environment and Life Sciences, University of Salford, Salford M5 4WT, UK. eelkord@qf.org.qa.

Abstract

Recent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.

KEYWORDS:

cancer progression; regulatory T cells; therapeutic targeting; tumor microenvironment; tumor-infiltrating lymphocytes

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center